Cost-Effectiveness of Umeclidinium/Vilanterol Versus Indacaterol/Glycopyrronium in Symptomatic patients with COPD in the UK

被引：0
|
作者：
Ismaila, Afisi S. [1 ]
Shah, Dhvani [2 ]
Martin, Alan [3 ]
Kendall, Robyn [4 ]
Noorduyn, Stephen [5 ]
Dasari, Priyadarsini [6 ]
Risebrough, Nancy A. [7 ]
Compton, Chris [8 ]
Noorduyn, Stephen G.
Risebrough, Nancy A. [7 ]
Compton, Chris [8 ]
Noorduyn, Stephen G.
机构：
[1] GSK, Value Evidence & Outcomes, Collegeville, PA USA
[2] ICON Plc, ICON Hlth Econ, Bridgewater, NJ USA
[3] GSK, Value Evidence & Outcomes, Brentford, England
[4] ICON Plc, ICON Hlth Econ, Vancouver, BC, Canada
[5] GSK, Value Evidence & Outcomes, Mississauga, ON, Canada
[6] ICON Plc, ICON Hlth Econ, Houston, TX USA
[7] ICON Plc, ICON Hlth Econ, Burlington, ON, Canada
[8] GSK, R&D Global Med, Brentford, England
来源：
EUROPEAN RESPIRATORY JOURNAL | 2023年 / 62卷
基金：
芬兰科学院;
关键词：
D O I：
10.1183/13993003.congress-2023.PA1328
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD
    Wedzicha, Jadwiga A.
    Banerji, Donald
    Chapman, Kenneth R.
    Vestbo, Jorgen
    Roche, Nicolas
    Ayers, Timothy
    Thach, Chau
    Fogel, Robert
    Patalano, Francesco
    Vogelmeier, Claus F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (23): : 2222 - 2234
  • [42] Effectiveness and Tolerability of LABA/LAMA Fixed-Dose Combinations Aclidinium/Formoterol, Glycopyrronium/Indacaterol and Umeclidinium/Vilanterol in the Treatment of COPD in Daily Practice - Results of the Non-Interventional DETECT Study
    Plate, Tanja
    Friedrich, Felix W.
    Beier, Jutta
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2020, 15 : 1335 - 1347
  • [43] A Uk Based Cost-Effectiveness Analysis Of Glycopyrronium Bromide A New Anti-Muscarinic Agent For The Maintenance Treatment Of Patients With COPD
    Malcolm, W. A.
    Keyzor, I.
    Radwan, A.
    Price, D. B.
    Asukai, Y.
    Ananthapavan, J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [44] Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD—a randomised controlled study
    Joerg Salomon
    Daiana Stolz
    Guido Domenighetti
    Jean-Georges Frey
    Alexander J. Turk
    Andrea Azzola
    Thomas Sigrist
    Jean-William Fitting
    Ulrich Schmidt
    Thomas Geiser
    Corinne Wild
    Konstantinos Kostikas
    Andreas Clemens
    Martin Brutsche
    Respiratory Research, 18
  • [45] The IMPACT Trial: Single Inhaler Triple Therapy fluticasone Furoate/Umeclidinium/Vilanterol Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: Analysis According to Smoking Status
    Halpin, D. M. G.
    Bardsley, S.
    Criner, G.
    Dransfield, M.
    Han, M. K.
    Jones, C. E.
    Kilbride, S.
    Lomas, D. A.
    Martinez, F.
    Pascoe, S.
    Singh, D.
    Wise, R.
    Lipson, D. A.
    Lange, P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [46] Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis
    Vogelmeier, Claus
    Zhong, Nanshan
    Humphries, Michael J.
    Mezzi, Karen
    Fogel, Robert
    Bader, Giovanni
    Patalano, Francesco
    Banerji, Donald
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2016, 11 : 3189 - 3197
  • [47] InforMing the PAthway of COPD Treatment (The IMPACT Study): Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: An Analysis Based on Baseline COPD Medication Use
    Singh, D.
    Criner, G. J.
    Dransfield, M. T.
    Halpin, D. M. G.
    Han, M. K.
    Jones, C. E.
    Kilbride, S.
    Lange, P.
    Lomas, D. A.
    Martinez, F. J.
    Pascoe, S. J.
    Wise, R. A.
    Lipson, D. A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [48] Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial
    Singh, Dave
    Worsley, Sally
    Zhu, Chang-Qing
    Hardaker, Liz
    Church, Alison
    BMC PULMONARY MEDICINE, 2015, 15
  • [49] Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial
    Dave Singh
    Sally Worsley
    Chang-Qing Zhu
    Liz Hardaker
    Alison Church
    BMC Pulmonary Medicine, 15
  • [50] Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
    Nicola C. Day
    Subramanya Kumar
    Gerard Criner
    Mark Dransfield
    David M. G. Halpin
    MeiLan K. Han
    C. Elaine Jones
    Morrys C. Kaisermann
    Sally Kilbride
    Peter Lange
    David A. Lomas
    Neil Martin
    Fernando J. Martinez
    Dave Singh
    Robert Wise
    David A. Lipson
    Respiratory Research, 21
12345